Anika Therapeutics
ANIK
162 hedge funds and large institutions have $429M invested in Anika Therapeutics in 2018 Q4 according to their latest regulatory filings, with 28 funds opening new positions, 38 increasing their positions, 66 reducing their positions, and 25 closing their positions.
12% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 25
1% more funds holding
Funds holding: 161 → 162 (+1)
0.29% less ownership
Funds ownership: 90.12% → 89.83% (-0.29%)
23% less capital invested
Capital invested by funds: $554M → $429M (-$125M)
33% less call options, than puts
Call options by funds: $625K | Put options by funds: $930K
42% less repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 66
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
+$4.85M |
| 2 |
Millennium Management
New York
|
+$3.59M |
| 3 |
Barrow, Hanley, Mewhinney & Strauss
Dallas,
Texas
|
+$2.61M |
| 4 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$2.03M |
| 5 |
SFM
Systematic Financial Management
Teaneck,
New Jersey
|
+$1.35M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$6.93M |
| 2 |
State Street
Boston,
Massachusetts
|
-$5.08M |
| 3 |
Kayne Anderson Rudnick Investment Management
Los Angeles,
California
|
-$4.69M |
| 4 |
Baird Financial Group
Milwaukee,
Wisconsin
|
-$3.23M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
-$2.62M |
ANIK Hedge Fund Activity: Q4 2018 in Review
162 of the 4,505 institutional investors tracked by Wall St. Rank reported a position in Anika Therapeutics (ANIK) for Q4 2018, worth a combined $429M — down 23% from $554M a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new ANIK positions and 25 closed out — a net gain of 3 holders — while 38 added to existing stakes and 66 trimmed.
The largest buyer was Marshall Wace, opening a new position worth an estimated $4.85M. The largest seller was Deutsche Bank, cutting an estimated $6.93M.
- 162 institutional investors held Anika Therapeutics (ANIK) as of Q4 2018, up from 161 in Q3 2018.
- Funds reported $429M of Anika Therapeutics stock for Q4 2018, down 23% quarter-over-quarter.
- 28 funds opened new Anika Therapeutics positions in Q4 2018 and 25 closed out, a net change of +3 holders.
- The largest Anika Therapeutics buyer in Q4 2018 was Marshall Wace, an estimated $4.85M added.
- The largest Anika Therapeutics seller in Q4 2018 was Deutsche Bank, an estimated $6.93M sold.
Based on aggregated 13F filings for Q4 2018.